Home LiteratureArticle Details
PMID: 15188458 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage.

Genes, chromosomes & cancer ·Vol. 40 ·No. 4 ·2004-08-00 ·Pages 342-8

Partheen K, Levan K, Osterberg L, Helou K, Horvath G

Abstract

Ovarian cancer is the leading cause of death among patients with gynecological cancers, but the biology of these tumors is still among the least understood of all major human malignancies. In this study, comparative genomic hybridization was used to determine chromosomal alterations in 98 stage III serous papillary adenocarcinomas. The tumors were grouped according to survival and the main prognostic factors stage and surgical outcome. There were chromosomal imbalances that were significantly more common in tumors from patients who died than in tumors from patients who survived: gains of 1q24-qter and losses of 4p, 4q31.1-qter, 5q12-q22, 8p, 16q, and X. Furthermore, we observed that gains of 8q23-8q24.2 and losses of 4p, 4q13-4q26, 4q31.1-qter, 5q12-q22, 8p, and 16q were significantly more common in tumors from patients with macroscopic residual tumor after primary surgery, compared to tumors from those who had undergone radical surgery. Gains of 3q13.3-qter, 6p, 7q21-q31, and 11q13-q23 and losses of 4q31.1-qter and 16q were more common in stage IIIc tumors than in stage IIIa+b tumors. On the basis of our results, we suggest that there are biological differences among the groups mentioned above and that absence of chromosomal aberrations in specific regions predicts a good clinical outcome for individual patients.

MeSH Terms
Chromosome Aberrations/classification Chromosome Deletion Cystadenocarcinoma, Papillary/genetics,pathology,surgery Cystadenocarcinoma, Serous/genetics,pathology,surgery Cytogenetic Analysis/methods Female Gene Amplification/genetics Humans Karyotyping Neoplasm Staging Ovarian Neoplasms/genetics,pathology,surgery Prognosis Survival Rate/trends Treatment Outcome
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Partheen Karolina
Department of Oncology, Göteborg University, Göteborg, Sweden. karolina.partheen@oncology.gu.se
Levan Kristina
Osterberg Lovisa
Helou Khalil
Horvath György
Article Info
Journal
Genes, chromosomes & cancer
Abbr.
Genes Chromosomes Cancer
ISSN
1045-2257
Published
2004-08-00
Pages
342-8
Language
English
Region
United States
NLM ID
9007329
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com